1.37  -0.03 (-2.14%)		12-26 16:00
Open: 1.38 High: 1.4 Volume: 3,397,089		Pre. Close: 1.4 Low: 1.36 Market Cap: 875(M)

Short term
Mid term
Targets	6-month :	1.69	1-year :	1.97
Resists	First :	1.45	Second :	1.69
Pivot price	1.33
Supports	First :	1.21	Second :	1.07
MAs	MA(5) :	1.35	MA(20) :	1.3
	MA(100) :	1.29	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	65.2	D(3) :	62.3
RSI	RSI(14): 57.9
52-week	High :	3.68	Low :	1.03

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ GERN ] has closed below upper band by 31.7%. Bollinger Bands are 19.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.4 - 1.41	1.41 - 1.42
Low:	1.34 - 1.35	1.35 - 1.36
Close:	1.36 - 1.37	1.37 - 1.38

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Wed, 24 Dec 2025
Geron (NASDAQ:GERN) Trading Up 4.9% - Time to Buy? - MarketBeat

Fri, 19 Dec 2025
Geron: From Launch Hype To Later-Line Gravity (NASDAQ:GERN) - Seeking Alpha

Thu, 18 Dec 2025
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Thu, 18 Dec 2025
Geron Corporation (GERN) Restructuring to Lower Operating Expenses as it Eyes Profitability in 2026 - Yahoo Finance

Wed, 17 Dec 2025
Geron (NASDAQ:GERN) Stock Price Up 5.6% - Here's What Happened - MarketBeat

Tue, 16 Dec 2025
Squarepoint Ops LLC Increases Stock Position in Geron Corporation $GERN - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	638 (M)
Shares Float	536 (M)
Held by Insiders	0.1 (%)
Held by Institutions	81.5 (%)
Shares Short	77,380 (K)
Shares Short P.Month	85,260 (K)

EPS	-0.12
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.38
Profit Margin	-43.7 %
Operating Margin	-29.5 %
Return on Assets (ttm)	-7.8 %
Return on Equity (ttm)	-29.6 %
Qtrly Rev. Growth	67 %
Gross Profit (p.s.)	0.15
Sales Per Share	0.28
EBITDA (p.s.)	-0.1
Qtrly Earnings Growth	0 %
Operating Cash Flow	-133 (M)
Levered Free Cash Flow	-94 (M)

PE Ratio	-11.42
PEG Ratio	0
Price to Book value	3.51
Price to Sales	4.76
Price to Cash Flow	-6.59

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.